NEW SP100 Scientific Plenary—Breakthroughs in Molecular Testing of Lung Cancer: A Pathologist’s and a Patient Advocate’s Perspective
8:00–9:15 am
1.0 CME/CE CREDITS
Pathologists have witnessed a revolution in the molecular understanding of lung cancer. In the rapidly developing area of personalized medicine, the CAP has teamed with the Association of Molecular Pathology (AMP) and the International Association for the Study of Lung Cancer (IASLC) to develop new guidelines for molecular testing now used to guide treatment of this disease, which strikes nearly 230,000 Americans each year.
Listen to one of the lead authors of the CAP/IASLC/AMP guidelines, Marc Ladanyi, MD, FCAP. Dr. Ladanyi will highlight the guidelines and provide an overview of lung cancer and how molecular testing is increasingly incorporated into the routine care of lung cancer patients.
Kim Norris, a UCLA Lung SPORE patient advocate and president of the Lung Cancer Foundation of America, will discuss how these new guidelines benefit patients and provide them with a greater understanding of the pathologist’s critical role in targeted therapy. Ms. Norris will share patient stories and discuss how to help patients understand the importance of their tissue samples.
Philip T. Cagle, MD, FCAP, editor of the award-winning publication, Archives of Pathology & Laboratory Medicine, will serve as moderator.
You will learn to:
- Describe the current state of lung cancer molecular testing standards and guidelines as they apply to EGFR and ALK assays and the ongoing evolution toward more extensive and comprehensive patient testing
- Evaluate new opportunities and responsibilities that allow you to play a central role on the health care team in the management of patients with lung cancer
Faculty
Philip T. Cagle, MD, FCAP
Marc Ladanyi, MD, FCAP
Kim Norris